Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy

References

• Reid MM. Chronic idiopathic thrombocytopenic purpura: incidence, treatment, and outcome. Arch Dis Child. 1995;72(2):125–128. DOI: 10.1136/adc.72.2.125
   PubMed Web of Science ®Google Scholar
• Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85(3):174–180.
   PubMed Web of Science ®Google Scholar
• AIEOP. Available at: https://www.aieop.org/web/
   Google Scholar
• Despotovic JM, Grimes AB. Pediatric ITP: is it different from adult ITP? Hematology Am Soc Hematol Educ Program. 2018;2018(1):405–411.
   PubMedGoogle Scholar
• Matzdorff A, Meyer O, Ostermann H, et al. Immune thrombocytopenia – current diagnostics and therapy: recommendations of a joint working group of DGHO, OGHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018;41:51–30.
   Web of Science ®Google Scholar
• Kuhne T. Diagnosis and management of immune thrombocytopenia in childhood. Hamostaseologie. 2017;37(1):36–44. DOI: 10.5482/HAMO-16-06-0017
   PubMed Web of Science ®Google Scholar
• Parodi E, Russo G, Farruggia P, et al. Management strategies for newly diagnosed immune thrombocytopenia in Italian AIEOP Centres: do we overtreat? Data from a multicentre, prospective cohort study. Blood Transfus. 2020;18(5):396–405.
   PubMed Web of Science ®Google Scholar
• Yong M, Schoonen WM, Li L, et al. Epidemiology of paediatric immune thrombocytopenia in the general practice research database. Br J Haematol. 2010;149(6):855–864. DOI: 10.1111/j.1365-2141.2010.08176.x
   PubMed Web of Science ®Google Scholar
• Kim TO, Despotovic JM. Primary and secondary immune cytopenias: evaluation and treatment approach in children. Hematol Oncol Clin North Am. 2019;33(3):489–506. DOI: 10.1016/j.hoc.2019.01.005
   PubMed Web of Science ®Google Scholar
• Neunert CE, Cooper N. Evidence-based management of immune thrombocytopenia: ASH guideline update. Hematology Am Soc Hematol Educ Program. 2018;2018(1):568–575.
   PubMed Web of Science ®Google Scholar
• Heitink-Polle KMJ, Uiterwaal C, Porcelijn L, et al. Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial. Blood. 2018;132(9):883–891. DOI: 10.1182/blood-2018-02-830844
   PubMed Web of Science ®Google Scholar
• Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. DOI: 10.1182/bloodadvances.2019000966
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhang L, Gao J, et al. Rituximab for children with immune thrombocytopenia: a systematic review. PLoS One. 2012;7(5):e36698. DOI: 10.1371/journal.pone.0036698
   PubMed Web of Science ®Google Scholar
• Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;386(10004):1649–1658. DOI: 10.1016/S0140-6736(15)61107-2
   PubMed Web of Science ®Google Scholar
• Cheng X, Fu L, Ma J, et al. Spotlight on eltrombopag in pediatric ITP in China: a long-term observational study in real-world practice. Blood Adv. 2021;5(19):3799–3806. DOI: 10.1182/bloodadvances.2020004110
   PubMed Web of Science ®Google Scholar
• Wire MB, Li X, Zhang J, et al. Modeling and simulation support eltrombopag dosing in pediatric patients with immune thrombocytopenia. Clin Pharmacol Ther. 2018;104(6):1199–1207. DOI: 10.1002/cpt.1066
   PubMed Web of Science ®Google Scholar
• Dionisi M, Cairoli S, Simeoli R, et al. Pharmacokinetic evaluation of eltrombopag in ITP pediatric patients. Front Pharmacol. 2021:6;12:772873.
   Web of Science ®Google Scholar
• Eltrombag. (n.d.). Summary of product characteristics.
   Google Scholar
• Giordano P, Lassandro G, Barone A, et al. Use of eltrombopag in children with chronic immune thrombocytopenia (ITP): a real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Front Med (Lausanne). 2020;28;7:66.
   Web of Science ®Google Scholar
• Frederiksen H, Maegbaek ML, Norgaard M. Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2014;166(2):260–267. DOI: 10.1111/bjh.12869
   PubMed Web of Science ®Google Scholar
• Cooper N, Hill QA, Grainger J, et al. Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified Delphi panel. Acta Haematol. 2021;144:418-426..
   PubMed Web of Science ®Google Scholar
• Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527–2536. Blood. 2018;131(6):709.
   PubMed Web of Science ®Google Scholar
• Lucchini E, Palandri F, Volpetti S, et al. Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. Br J Haematol. 2021;193:386–396.
   Web of Science ®Google Scholar
• Oka S, Ono K, Nohgawa M. The association of lymphocyte phenotypes and outcomes after discontinuing eltrombopag in immune thrombocytopenia. Int J Clin Pract. 2021;75(5):e14057.
   PubMed Web of Science ®Google Scholar
• Cuker A, Despotovic JM, Grace RF, et al. Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: expert consensus based on the RAND/UCLA modified Delphi panel method. Res Pract Thromb Haemost. 2021;5(1):69–80. DOI: 10.1002/rth2.12457
   PubMed Web of Science ®Google Scholar
• Zaja F, Carpenedo M, Barate C, et al. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: real-world recommendations. Blood Rev. 2020:41:100647.
   PubMed Web of Science ®Google Scholar